Dexcom, Inc. Files 8-K with Financial Updates
Ticker: DXCM · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, operations
Related Tickers: DXCM
TL;DR
Dexcom dropped its 8-K on Feb 13, 2025. Financials and exhibits are in.
AI Summary
On February 13, 2025, Dexcom, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance for the period ending on the same date. Dexcom, Inc. is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides investors with crucial, up-to-date financial information and operational details for Dexcom, Inc., enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.
Key Players & Entities
- DEXCOM INC (company) — Registrant
- February 13, 2025 (date) — Date of Report
- San Diego, CA (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing by Dexcom, Inc.?
The primary purpose of this 8-K filing is to report on Dexcom, Inc.'s Results of Operations and Financial Condition, and to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on February 13, 2025.
Where is Dexcom, Inc.'s principal executive office located?
Dexcom, Inc.'s principal executive office is located at 6340 Sequence Drive, San Diego, CA 92121.
In which state is Dexcom, Inc. incorporated?
Dexcom, Inc. is incorporated in Delaware.
What is the SIC code for Dexcom, Inc.?
The Standard Industrial Classification (SIC) code for Dexcom, Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-02-13 16:03:33
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global
Filing Documents
- dxcm-20250213.htm (8-K) — 28KB
- dxcm12312024-exhibit991.htm (EX-99.1) — 291KB
- dxcm-20250213_g1.jpg (GRAPHIC) — 108KB
- 0001093557-25-000029.txt ( ) — 708KB
- dxcm-20250213.xsd (EX-101.SCH) — 2KB
- dxcm-20250213_lab.xml (EX-101.LAB) — 21KB
- dxcm-20250213_pre.xml (EX-101.PRE) — 12KB
- dxcm-20250213_htm.xml (XML) — 3KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 13, 2025, DexCom, Inc. ("Dexcom") issued a press release announcing its financial results for the quarter and year ended December 31, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of Dexcom under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Number Description 99.1 Press release dated February 13 , 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Date: February 13, 2025